Iwona Ługowska

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Funda Meric‐Bernstam, Vicky Makker, Ana Oaknin et al. · Journal of Clinical Oncology · 2023 · 767 citations · Full text

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

Alessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo et al. · The Lancet Oncology · 2017 · 473 citations

Tumor Biology, Surgical Oncology, Malignant Disease +10

Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups

Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo et al. · Journal of Clinical Oncology · 2020 · 245 citations · Full text

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Shubham Pant, Martin Schüler, Gopa Iyer et al. · The Lancet Oncology · 2023 · 175 citations · Full text

Fgfr Alterations, Medicine, Pathology +7

Preoperative hypofractionated radiotherapy in the treatment of localized soft tissue sarcomas

Hanna Koseła-Paterczyk, Milena Szacht, Tadeusz Morysiński et al. · European Journal of Surgical Oncology · 2014 · 105 citations

Surgical Oncology, Radiation Therapy, Soft Tissue Surgery +4